

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27

**FoRSHE-X digital health intervention to improve the quality of life during chemotherapy among gynecological cancer survivors in Indonesia: A protocol for a pilot and feasibility study**

Yati Afiyanti<sup>1</sup>, Dyah Juliastuti<sup>2\*</sup>, Winnie Kwok Wei So<sup>3</sup>, Ariesta Milanti<sup>4</sup>, Lina Anisa Nasution<sup>1,5</sup>,  
Aprilia Dian Prawesti<sup>1</sup>

<sup>1</sup> Faculty of Nursing, Universitas Indonesia, Depok, Indonesia

<sup>2</sup> Program Study of Nursing, Faculty of Health Sciences, Universitas Ichsan Satya, South Tangerang, Indonesia

<sup>3</sup> The Nethersole School of Nursing, The Chinese University of Hong Kong, Hong Kong.

<sup>4</sup> Faculty of Nursing and Midwifery, Binawan University, Jakarta, Indonesia

<sup>5</sup> Program Study of Nursing, Faculty of Sport and Health Education, Universitas Pendidikan Indonesia, Bandung, Indonesia

\*Corresponding Author

Email address: [dyahjuliastuti2@gmail.com](mailto:dyahjuliastuti2@gmail.com)

Short Title: Digital intervention FoRSHE-X, quality of life during chemotherapy, and gynecological cancer survivors

## 28 **Contributorship**

29 YA and DJ researched literature and conceived the study. LAN and ADP were involved in  
30 protocol development, gaining ethical approval, patient recruitment, and data analysis for  
31 instrument validity testing. AM and DJ wrote the first draft of the manuscript. YA and WKWS  
32 reviewed the manuscript. All authors edited and approved the final version of the manuscript

## 33 **Conflicting interests**

34 The authors declare no conflict of interest.

## 35 **Funding**

36 This work was supported by the Hibah Publikasi Terindeks International (PUTI) Q1 from the  
37 Universitas Indonesia (Grant number: NKB-343/UN2.RST/HKP.05.00/2023) received by YA.

## 38 **Ethical approval**

39 The ethics committees of Nursing Faculty, Universitas Indonesia (REC number: KET-  
40 136/UN2.F12.D1.2.1/PPM.00.02/2023) and Dharmais Cancer Hospital (REC number:  
41 259/KEPK/VIII/2023) approved this study.

42

43

44

## 45 **Abstract**

46 Most Indonesian gynecological cancer survivors have unmet supportive care needs during  
47 chemotherapy, which may lower their quality of life and discontinue the treatment. Digital health  
48 intervention can address this issue. This pilot investigation aims to (1) examine the feasibility  
49 and acceptability of a Fighting on distResS, Self-efficacy, Health Effects, and seXual issues  
50 (FoRSHE-X) intervention and (2) evaluate prospectively the impact of the study implementation  
51 on the level of distress, self-efficacy, side effects' knowledge and management, and sexual  
52 quality of life using the RE-AIM (Reach Effectiveness, Adoption, Implementation, and  
53 Maintenance) framework. This is a non-randomized pilot and feasibility study. We will recruit  
54 women diagnosed with gynecological cancer undergoing chemotherapy to participate in the  
55 FoRSHE-X intervention consisting of ten weeks of social media-based education and  
56 telecoaching. We will evaluate the primary outcomes of study feasibility and acceptability, and  
57 the secondary outcomes of study impacts at three time points with quantitative and qualitative  
58 inquiries. We anticipate a minimum of 30 participants to enroll in the study and complete the  
59 assessment. We will disseminate results through conferences and peer-reviewed scientific  
60 journals. This study will imply whether a definitive trial to evaluate the potential benefits of the  
61 FoRSHE-X is viable and how it should proceed. The protocol can aid researchers or nurses in  
62 implementing this approach in their study or practice.

63 *Keywords:* chemotherapy, digital health intervention, gynecology, cancer, social media,  
64 telenursing, telecoaching

65

## 66 Introduction

67 Cancer is the second leading cause of mortality in the world, with 10 million cancer-  
68 related deaths estimated to occur in 2020 [1]. According to the World Health Organization  
69 (WHO), low- and middle-income countries (LMICs) bear the most tremendous burden of cancer  
70 [2]. More than 70% of the 10 million cancer-related fatalities were in LMICs [2]. In the case of  
71 cervical cancer, the disparity is even more prominent, as 90% of new cases and deaths happened  
72 in LMICs [1]. Other gynecological cancer types, including ovarian and uterine corpus cancer,  
73 also contribute significantly to the burden of cancer in LMICs [1].

74 Given the immense cancer concerns in many LMICs, reducing premature mortality  
75 through promoting well-being has been listed as one of the targets (target 3.4) of the Sustainable  
76 Development Goals (SDG) [3]. Therefore, increasing the country's capacity to provide quality  
77 care across the cancer care continuum, including survivorship care, is necessary. Although  
78 cancer has been set among the top national catastrophic diseases to prioritize in Indonesia [4],  
79 survivorship care is still suboptimal [5].

80 An individual can be considered a cancer survivor from diagnosis through the balance of  
81 his or her life [6]. Earlier studies showed that most Indonesian gynecological cancer survivors  
82 had unmet needs, especially regarding information and comprehensive care [7,8]. The survivors  
83 reported that they hardly had enough time and opportunity to discuss with the health providers,  
84 particularly the nurses, the physical, psychosocial, sexual, and other issues that arose during and  
85 after cancer therapy [7,9]. The availability of cancer survivorship educational media in Bahasa  
86 Indonesia is low, and most Indonesian cancer survivors also have inadequate health literacy  
87 [10,11]. These conditions might hamper the continuity of care and lead to an unanticipated  
88 relapse [12]. In addition, unmet needs were also found to be linked to the low quality of life of

89 gynecological cancer survivors in Indonesia [13,14].

90 In the digital era, many digital devices and platforms, including mobile phones, mobile  
91 applications, websites, and wearable devices, are increasingly used in healthcare services [15].  
92 Digital technologies can be harnessed to enhance communication between cancer patients and  
93 healthcare providers [16]. Indeed, prior systematic reviews showed promising findings of the  
94 digital interventions' effects in addressing cancer survivors' unmet health information needs and  
95 physical and psychosocial support [17–20]. Digital interventions can serve as an excellent means  
96 to assist cancer survivors in managing their disease and treatment side effects, thereby improving  
97 their quality of life and the continuity of the therapy [17,20,21]. Digital health interventions were  
98 also found to be similarly effective as usual care to improve the quality of life among cancer  
99 survivors [21]. Given their broad potential benefits, the WHO has recommended using digital  
100 technologies to strengthen the national health system and achieve the vision of health for all [15].

101 Nursing intervention for gynecological cancer survivors has not yet been well developed  
102 to provide comprehensive and culturally sensitive services in Indonesia, incorporating new  
103 technology. Gynecological cancer survivors undergoing cancer therapy will have a better  
104 prognosis if they can complete their treatment and understand health management during  
105 chemotherapy. Throughout therapy, gynecological cancer survivors have multidimensional needs  
106 that, if not well anticipated, may result in therapy termination, relapse, or even death [22]. These  
107 needs encompass prevention of recurrence, adopting a healthy lifestyle, managing physical  
108 symptoms arising from cancer and its therapy, managing psychosocial and sexual issues, and  
109 obtaining information related to self-care [23,24].

110 We are developing a sustainable intervention that embraces digital technologies to  
111 overcome the communication barriers between cancer survivors and healthcare providers and to  
112 improve self-management for the physical, mental, social, and sexual effects of chemotherapy in

113 the patient’s life. We aim to leverage a digital health intervention to address the insufficiency of  
114 survivorship care for Indonesian gynecological cancer survivors by combining social media-  
115 based education and telecoaching. Therefore, we propose a digital solution called Fighting on  
116 distRes, Self-efficacy, Health Effects, and seXual issues (FoRSHE-X).

117 We will conduct a study to examine the feasibility and acceptability of the FoRSHE-X  
118 intervention using the RE-AIM (Reach, Effectiveness, Adoption, Implementation, and  
119 Maintenance) Framework with the specific primary objectives are as follows (1) to examine the  
120 eligibility and acceptability of the participants towards the study intervention, (2) to evaluate the  
121 feasibility of digital education, telecoaching, and intervention facilitators, (3) to evaluate the  
122 process of the implementation, and (4) to evaluate the intervention sustainability or participants’  
123 involvement over time. Additionally, the secondary objective is to evaluate the impact of the  
124 study intervention to the level of anxiety, self-efficacy, side effects’ knowledge and  
125 management, and sexual quality of life and the participants’ perspectives towards this study  
126 intervention.

## 127 **Methods**

### 128 **Design**

129 We will conduct a non-randomized pilot and feasibility study in which all participants  
130 will receive the FoRSHE-X intervention. We will adapt the RE-AIM Framework to evaluate the  
131 feasibility and pilot study as outlined by O’Brien and colleagues [25] (See Table 1). The RE-  
132 AIM dimensions represent multiple tasks of complex multi-components intervention [25]. This  
133 feasibility study asks questions: Can a definitive trial to assess the effect of an intervention be  
134 done? Should we proceed with it, and how? [26]. A pilot study is a subset of a feasibility study in  
135 which the future trial is entirely or partially performed on a smaller scale [26]. Quantitative and

136 qualitative approaches will be used to achieve the study objectives.

137

138 **Table 1. Defining objectives and data collection using RE-AIM Framework**

RE-AIM Dimension	Objectives	Quantitative Data	Qualitative Data
<b>Reach</b>	To examine the eligibility and acceptability of the participants	Demographic and clinical data  Acceptance of the research invitation	Participants' experience and perspective on the acceptability of the recruitment process and involvement in this study.  Facilitators' concerns and challenges in recruiting potential participants.
<b>Effectiveness</b>	To evaluate the impact of the intervention outcomes	Distress Thermometer Chemotherapy side effects Self-efficacy SQoL-F	Participant's experience and perspectives on the effect of FoRSHE-X intervention towards their health
<b>Adoption</b>	To evaluate the feasibility of digital education, telecoaching, and intervention agents	Complete response to the questionnaire Facilitator's satisfaction	Researcher daily memoing  Facilitators' experience toward digital education and telecoaching
<b>Implementation</b>	Evaluate the process of implementation (usability)	Coaching log book  Proof of telecoaching attendance	Participants' desire and challenges to follow the intervention
<b>Maintenance</b>	Evaluate the intervention sustainability or participants' involvement over time	Participant's diary notes Participant's adherence on telecoaching Follow-up rate Participant retention	Participant's experience and perspectives towards digital education and telecoaching activities

139

## 140 **Study setting and participants**

141 The study will be initiated at the Dharmais National Cancer Center (DNCC) in Jakarta,  
 142 Indonesia. It is a comprehensive cancer center providing cancer care, education, research, and  
 143 data in Indonesia. As a national referral hospital, it serves as the central hub for cancer diagnosis,  
 144 treatment, and management, serving patients from Jakarta and nationwide. DNCC offers  
 145 chemotherapy in several units, including the Systemic Therapy Unit, One Day Care Unit, and

146 Inpatient Unit.

147 We will recruit participants in the DNCC's One Day Dare Unit and inpatient units. The  
148 eligibility criteria will be (1) female aged 18 years or older, (2) being diagnosed with  
149 gynecologic cancer (including cervical, ovarian, uterine, vulvar, vaginal, and fallopian tube  
150 cancer), (3) receiving chemotherapy at the DNCC, (4) having a smartphone, (5) willing and  
151 physically or cognitively able to participate in the study and follow the study procedures, and (6)  
152 being able to communicate in Bahasa Indonesia.

153 On the other hand, patients diagnosed with severe neurological conditions such as  
154 unmanaged mental health diagnosis, current metastases to the brain, delirium, and dementia, as  
155 well as those with any prior history of receiving chemotherapy or cancer recurrence, will be  
156 excluded because these conditions might confound cognitive functioning [27] Patients with  
157 severe hearing or visual impairment that would prevent them from communicating and using the  
158 educational digital material will also be excluded. Another exclusion criterion is patients who are  
159 single, divorced, or widowed with no sexual partner.

160 Thirty participants will be recruited using a convenience sampling technique to enroll in  
161 the study. A sample size of 30 participants is considered sufficient for evaluating the feasibility  
162 of a clinical trial and providing preliminary estimates of the effect sizes of the study outcomes  
163 [27].

## 164 **Outcomes measures**

### 165 **Primary outcomes**

166 The primary outcomes will be examined through quantitative and qualitative data on  
167 study feasibility and acceptability. The data will cover participant recruitment and retention, the



168 implementation of the intervention, and participant satisfaction.

169           The research team will maintain a log book to record (1) the number of gynecological  
170 cancer patients approached to participate in the study, (2) the number of patients who met the  
171 eligibility criteria, (3) the number of patients who sign informed consent, (4) the number of  
172 participants who received the intervention and were retained in the study until the final follow-up  
173 (week 10), (5) the number of participants who provided a complete response to questionnaires,  
174 (6) the number of participants who complete any measures, regardless of their completion rates,  
175 and (7) the number of participants who completed the prescribed number of telecoaching  
176 sessions.

177           We will carry out a qualitative evaluation to assess (1) intervention adherence, (2)  
178 acceptability of the recruitment processes, intervention design and delivery, and outcome  
179 measurements, (3) facilitators and barriers to recruitment and intervention delivery, and (4)  
180 participant satisfaction. Qualitative data will be collected through semi-structured interviews  
181 with the participants after the study's completion. An experienced qualitative researcher will  
182 conduct the interviews which will be recorded using an audiotape and transcribed by a research  
183 assistant.

## 184 **Sociodemographic and clinical variables**

185           We will use a questionnaire to collect participants' sociodemographic data (i.e., age,  
186 education, marital status, employment, ethnicity, and religious affiliation). We will also obtain  
187 clinical data at baseline from the participant's medical record, including gynecological cancer

188 type and stage and cancer treatment details.

## 189 **Secondary outcomes**

### 190 **Distress thermometer**

191 Distress is defined by the National Comprehensive Cancer Network (NCCN) as a  
192 "multifactorial unpleasant emotional experience of a psychosocial, and or spiritual nature that  
193 may interfere with the ability to cope effectively with cancer, its physical symptoms, and its  
194 treatment [28]. The NCCN recommended that distress be recognized, monitored, and managed  
195 sufficiently and timely [28]. The NCCN Distress Management Panel also developed the Distress  
196 Thermometer (DT), which originated from Roth's study [29], for the initial distress screening.  
197 The DT is a single-item rating scale from 0 (no distress) to 10 (extreme distress) [28].  
198 Participants will be asked to choose the number that best describes the distress level they have  
199 experienced over the past week, which could be related or unrelated to cancer. Meta-analyses of  
200 studies conducted in Asia and non-English-speaking countries suggested that the optimal cut-off  
201 point of DT was four [30,31]. Therefore, participants who score less than four on the DT are  
202 noted to experience mild distress [28], whereas a distress level of  $\geq$  four or above indicates a  
203 clinically significant distress level [28]. The DT has been adapted and validated by plenty of  
204 studies assessing patients with different cancer types in various languages and countries[28],  
205 including Indonesia [32]. The Bahasa Indonesia version of DT, which the NCCN has also  
206 verified, will be used in this study to measure the distress level of the participants at baseline and  
207 follow-up.

### 208 **Knowledge and practice regarding chemotherapy side effects**

209 At baseline and follow-up, the participants will be asked to indicate their knowledge  
210 about chemotherapy side effects, how they manage them, and whether they experienced those

211 symptoms in the past week. These outcomes will be measured using the chemotherapy side  
212 effect questionnaire, outlined by Almohammadi et al [33] will be adopted for this study. The  
213 questionnaire consists of two subsets. The first part assesses participants' knowledge of 16  
214 common side effects of chemotherapy, such as nausea and vomiting, fatigue, diarrhea and  
215 constipation, mouth ulcers and sores, hair loss, and sexual issues [33]. Yes/no responses will be  
216 used in this part of the questionnaire. The second part has seven items to examine the practice of  
217 side effect management, for example, "I measure my body temperature" and "I avoid eating  
218 spicy or fatty foods." We create four-scale Likert responses (never, seldom, often, and always) in  
219 this practice questionnaire. In our prior work, these side effect-related questionnaires have  
220 demonstrated their validity and reliability (Cronbach's alpha of 0.720 and 0.708, respectively).

### 221 **Self-efficacy**

222 Self-efficacy, posited by Bandura as a strong predictor of behavior, is conceptualized as  
223 the perceived capability to perform specific actions that are needed to achieve particular goals  
224 [34,35]. Numerous studies have shown the role of self-efficacy in improving self-management  
225 among patients with chronic diseases, including cancer [36,37].

226 The self-efficacy for managing chronic disease 6-item scale (SEMCD6) initially  
227 developed by the Stanford Patient Education Research Center will be used to measure the  
228 participants' self-efficacy [38]. This questionnaire is brief and easy to administer as it only  
229 contains six items with a 1-10 Likert scale ranging from 1 'not at all confident' to 10 'totally  
230 confident' to indicate how confident a patient is in managing the disease symptoms [38] The  
231 scale's total score is the mean score over at least four of the six items [38] A higher score  
232 indicates a higher level of self-efficacy [38]. The original version of this SEMCD6 was proven  
233 valid and reliable in patients with chronic diseases [38]. Previous studies have shown satisfactory  
234 psychometric properties of the several versions of SEMCD6, e.g., Spanish, German, Swedish,

235 and Portuguese [39–41]. This study has assessed the validity and reliability of the Bahasa  
236 Indonesia version of SEMCD6. The Cronbach's alpha value of the SEMCD6 Bahasa Indonesia  
237 version is 0.813.

### 238 **Sexual quality of life (SQoL-F)**

239 Sexual quality of life is the primary outcome of our future RCT and will be measured at  
240 baseline and follow-up using the Sexual Quality of Life-Female (SQOL-F). SQOL-F was  
241 initially designed by Symonds et al. using data sets from women's health surveys in the United  
242 Kingdom and the United States to examine how female sexual dysfunction impacts women's  
243 sexual quality of life [42]. This tool comprises 18 questions that capture sexual self-esteem,  
244 emotional well-being, and relationship issues in women [42]. Each item is rated on a six-point  
245 Likert scale ("completely agree" to "completely disagree"). Questions numbers 1, 5, 9, 13, and  
246 18 have reversed scoring. Therefore, the total score ranges between 18 and 108 [42]. A higher  
247 score indicates a higher level of sexual quality of life [42].

248 SQOL-F has been translated into some languages, for example, Iranian [43] Portuguese  
249 [44], Turkish [45] and Indonesia [46]. In the prior work of this study, the Bahasa Indonesia  
250 version of SQOL-F is valid and reliable (Cronbach's Alpha = 0.751) among Indonesian  
251 gynecological cancer survivors.

### 252 **FoRSHE-X intervention**

253 The main components and timeframe of the intervention are summarized in Table 2. The  
254 FoRSHE-X intervention consists of social media-based education and telecoaching. It will be  
255 implemented in two phases: Phase I will last six weeks, and Phase II will last for four weeks.

### 256 **Social media-based education**

257 We developed digital educational media, video and infographics, based on clinical

258 guidelines [47] to equip patients with valuable insights and strategies for effectively managing  
259 the physical, psychological, and sexual issues that may arise during their treatment journey. The  
260 educational contents consist of management of distress, pain, fatigue, anemia, risk of falling, hair  
261 fall, skin problems, sleep problems, difficulty breathing, bleeding, dehydration, constipation,  
262 diarrhea, loss of taste and smell, nausea and vomiting, weight loss, edema, sexual issues, and  
263 infertility. Our educational materials have been crafted to be visually engaging, featuring eye-  
264 catching graphics paired with clear and concise descriptions in Bahasa Indonesia to ensure  
265 accessibility and understanding for all patients. Recognizing the prevalence and accessibility of  
266 social media, we have chosen to leverage the power of Instagram, one of Indonesia's most widely  
267 used social media platforms, as the vehicle through which we provide this patient education.

## 268 **Telecoaching**

269 Telecoaching, a purposeful and patient-centered intervention carried out by certified  
270 nurse coaches using WhatsApp video calls, is organized around a ten-step procedure designed to  
271 empower and support the participants in applying the knowledge they have obtained from our  
272 social media-based education to manage the arising problems related to cancer and  
273 chemotherapy. The ten steps are (1) building trust and setting the agenda, (2) finding the inner  
274 drive, (3) addressing hidden issues, (4) clarifying orientation, (5) defining goals, (6) identifying  
275 options, (7) managing barriers, (8) getting support, (9) taking action, and (10) getting feedback.

276 The first phase lays a solid foundation for the coaching partnership by establishing trust  
277 and planning the agenda. The participants' inner motivation must then be tapped in step two to  
278 ignite their desire for proactive self-management. The subsequent step will address concerns that  
279 may be hidden and obstruct growth. Step four, clarifying orientation, is crucial in coordinating  
280 the patient's focus with their health objectives. The joint definition of specific objectives and

281 selecting workable solutions to meet those objectives make up steps five and six. In steps seven  
 282 and eight, the participants will be coached to develop strategies for overcoming obstacles and  
 283 exploring avenues of external support. Step nine guides patients to take decisive actions after  
 284 establishing goals and plans. Lastly, receiving feedback in step 10, which brings the coaching  
 285 process full circle, guarantees that it is dynamic, flexible, and highly responsive to the changing  
 286 needs and achievements of the individual.

287

288 Table 2. Activities and timeframe of the FoRSHE-X digital intervention

Phase	Week	Activity	Indicator
Working Phase I	I	Digital education, Baseline data collection (T0)	Knowledge of chemotherapy side effects (physical, psychological, sexual)
	II	Telecoaching session 1	Distress management
	III	Telecoaching session 2	Physical side effects management
	IV	Telecoaching session 3	Quality of sexual relationship
	V	Telecoaching session 4	Self-efficacy
	VI	Evaluation (T1)	
Working Phase II	VII	Telecoaching session 5 ( <i>on demand</i> )	
	VIII	Telecoaching session 6 ( <i>on demand</i> )	Side effects management
	IX	Telecoaching session 7 ( <i>on demand</i> )	
	X	Evaluation (T2)	

## 289 Data Analyses

290 Descriptive statistics of participants' clinical and demographic characteristics and all  
 291 study outcomes will be reported. The recruitment and retention rates will be computed to

292 determine the feasibility of a full RCT. A future complete RCT will be deemed feasible if the  
293 recruitment rate is at least 50% and the retention rate is at least 50%. Response rates to  
294 questionnaires, follow-up rates, and intervention adherence rates will also be calculated to  
295 provide further evidence for the feasibility of a definitive RCT. For the secondary objective, we  
296 will compare the longitudinal quantitative outcomes at three-time points (before, at the middle,  
297 and after the interventions) using the paired t-test (for continuous variables) and McNemar's test  
298 (for categorical variables) to evaluate changes at follow-up.

299 Qualitative data will be analyzed using content analysis by the research team's qualitative  
300 researchers. The team will develop a codebook based on the study objective and framework. The  
301 predetermined codes include acceptability, implementation, facilitators, barriers, and satisfaction.  
302 A qualitative researcher will code the transcripts once the final codes have been defined and  
303 agreed upon. Emerging codes can be added to the codebook during the analysis. After the  
304 analysis is finished, a detailed description of the findings will be reported. The qualitative  
305 findings will inform the acceptability of the study and the strategies or best practices of the study  
306 protocol.

## 307 **Governance**

308 The core team for this research consists of nurses with expertise in cancer care. The  
309 principal investigator is a professor of nursing who will oversee the study and deliver the  
310 telecoaching intervention. The research team members include nurses working in academia and  
311 at the DNCC. The nurses at DNCC will help provide a list of patients who may be eligible. In  
312 addition, a medical oncology consultant will also be involved in the study implementation

313 process.

## 314 **Research Ethics**

315 Before the research activities commence, the participants will be provided with an explanation of  
316 the activities to be conducted and their rights, as detailed in the information sheet. The  
317 participants will be able to ask questions about any unclear aspects and have the right to  
318 participate in this research voluntarily. Subsequently, if a participant agrees to be involved in this  
319 study, she will sign the Informed Consent Form.

## 320 **Compensation**

321 Participants will receive an internet data plan worth IDR 100,000 per month for the 2.5-month  
322 duration of the research activities. Additionally, a compensation of IDR 100,000 will be provided  
323 to each participant at the end of the FoRSHE-X digital intervention to offset the time spent  
324 participating in this study. Furthermore, the participants who will also be interviewed after the  
325 provision of digital education will receive IDR 100,000 each as compensation for transportation  
326 and time used during the interview process.

## 327 **Discussion**

328 This study will examine whether a definitive trial to evaluate the potential benefits of the  
329 FoRSHE-X intervention that combines digital education and nurse-led telecoaching is viable and  
330 how it should proceed. Feasibility comprises the practicability of implementing the trial,  
331 including participant recruitment and retention, intervention delivery, and data collection. This  
332 study will also seek to determine appropriate and acceptable outcome measures to be included in  
333 the full RCT. As such, the intervention will be given to everyone who participated in this  
334 feasibility and pilot study. Nevertheless, by using this approach, we cannot test the



335 randomization strategy for the subsequent RCT.

336 Exploring the participants' perspectives and experiences will also provide valuable  
337 insights into the acceptability of the study. We will assess how well the FoRSHE-X intervention  
338 was received and whether participants found it suitable and beneficial. Potential challenges,  
339 uncertainties, and strategies to improve them will also be explored by the participants, including  
340 those who drop out of the study. The qualitative part of the study can also help identify other  
341 potential impacts of the intervention and its interaction with the context in which it is  
342 implemented.

343 Study participants being recruited only from one hospital may limit the generalizability of  
344 the results. In this situation, the research findings will likely predominantly reflect the  
345 characteristics and experiences of the individuals involved in the study. As a result, the findings  
346 might not be readily applicable to a population that is more diverse or geographically separated,  
347 such as people who reside in rural areas with little access to online resources. Rural communities  
348 often face particular difficulties in gaining access to healthcare and technology, which may  
349 substantially impact how they respond to digital interventions like the one under study.  
350 Consequently, while the results may be insightful for the hospital's patient population, they  
351 should be considered relevant to a larger, more diverse population, especially those with limited  
352 internet access and lower educational levels.

353 The primary outcome of the FoRSHE-X intervention will be the sexual quality of life.  
354 Using telecoaching to improve the sexual quality of life for participants and their spouses can be  
355 a promising approach, although it may come with several possible difficulties. Firstly,  
356 discussions about private matters may give rise to privacy issues, limiting participants' openness  
357 and willingness to engage fully in telecoaching sessions. Secondly, participants in coaching  
358 programs often encounter various challenges in implementing the coaching recommendations

359 effectively. One potential major challenge is the resistance to change, as people tend to be more  
360 comfortable with their existing mindset and habits. Skills and patience may be needed to  
361 overcome such resistance. Thirdly, environmental or resource constraints can be another  
362 challenge for this study. Particularly for those living in suburban or rural areas, technological  
363 obstacles like poor internet connectivity may hinder effective and smooth communication during  
364 sessions. We will explore the participants' perspectives to address the potential challenges of the  
365 trial.

366 The FoRSHE-X digital intervention is expected to enhance the self-efficacy of  
367 gynecologic cancer survivors in preventing and addressing obstacles that may hinder them from  
368 continuing therapy and preparing for the post-treatment period. This intervention can connect  
369 patients with healthcare teams without space and time constraints. The utilization of digital  
370 technology is believed to expand the reach of healthcare services and enhance patient  
371 participation in their own sustainable self-care. The FoRSHE-X digital intervention has the  
372 potential to meet the supportive care needs of gynecologic cancer survivors undergoing  
373 chemotherapy.

## 374 **Acknowledgments**

375 The authors would like to thank the gynaecological cancer participants who will involve in the  
376 pilot of this study and Dharmais Cancer Hospital clinicians for their invaluable support and guide  
377 for the development and the implementation of this research project.

## 378 **References**

- 379 1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global  
380 Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for  
381 36 Cancers in 185 Countries. *CA Cancer J Clin.* 2021;71(3):209–49.

- 382 2. WHO International Agency for Research on Cancer. Estimated number of deaths in 2020,  
383 all cancers, both sexes, all ages [Internet]. 2020 [cited 2023 Aug 23]. p. 1–12. Available  
384 from: [https://gco.iarc.fr/today/online-analysis-](https://gco.iarc.fr/today/online-analysis-pie?v=2020&mode=population&mode_population=income&population=900&population_s=900&key=total&sex=0&cancer=39&type=1&statistic=5&prevalence=0&population_group=0&ages_group%5B%5D=0&ages_group%5B%5D=17&nb_items=7&group)  
385 [pie?v=2020&mode=population&mode\\_population=income&population=900&population](https://gco.iarc.fr/today/online-analysis-pie?v=2020&mode=population&mode_population=income&population=900&population_s=900&key=total&sex=0&cancer=39&type=1&statistic=5&prevalence=0&population_group=0&ages_group%5B%5D=0&ages_group%5B%5D=17&nb_items=7&group)  
386 [s=900&key=total&sex=0&cancer=39&type=1&statistic=5&prevalence=0&population\\_gr](https://gco.iarc.fr/today/online-analysis-pie?v=2020&mode=population&mode_population=income&population=900&population_s=900&key=total&sex=0&cancer=39&type=1&statistic=5&prevalence=0&population_group=0&ages_group%5B%5D=0&ages_group%5B%5D=17&nb_items=7&group)  
387 [oup=0&ages\\_group%5B%5D=0&ages\\_group%5B%5D=17&nb\\_items=7&group](https://gco.iarc.fr/today/online-analysis-pie?v=2020&mode=population&mode_population=income&population=900&population_s=900&key=total&sex=0&cancer=39&type=1&statistic=5&prevalence=0&population_group=0&ages_group%5B%5D=0&ages_group%5B%5D=17&nb_items=7&group)
- 388 3. United Nations. Sustainable Development Goal 3: Ensure healthy lives and promote well-  
389 being for all at all ages [Internet]. 2023 [cited 2023 Aug 23]. Available from:  
390 <https://sdgs.un.org/goals/goal3>
- 391 4. Ministry of Health Republic of Indonesia. The Ministry of Health ensures that services for  
392 the four catastrophic diseases can be conducted at Regional General Hospitals in  
393 Districts/Cities [Internet]. 2022 [cited 2023 Aug 24]. p. 1–7. Available from:  
394 [https://www.kemkes.go.id/article/view/22122400004/kemenkes-pastikan-layanan-4-](https://www.kemkes.go.id/article/view/22122400004/kemenkes-pastikan-layanan-4-penyakit-katastropik-dapat-dilakukan-di-rsud-kabupaten-kota.html)  
395 [penyakit-katastropik-dapat-dilakukan-di-rsud-kabupaten-kota.html](https://www.kemkes.go.id/article/view/22122400004/kemenkes-pastikan-layanan-4-penyakit-katastropik-dapat-dilakukan-di-rsud-kabupaten-kota.html)
- 396 5. Afiyanti Y, Komatsu H, Jagdish P, Milanti A, Nilmanat K, Lai Y hur, et al. Growth and  
397 development of oncology nursing in Asia. *Ann Palliat Med*. 2023 Jan;(4):1–12.
- 398 6. National Cancer Institute. Survivorship terms [Internet]. 2022 [cited 2023 Sep 13].  
399 Available from: <https://cancercontrol.cancer.gov/ocs/definitions>
- 400 7. Afiyanti Y, Milanti A, Rosdiana M, Juliastuti D. Deficient Health Care Services as  
401 Barriers to Meet Care Needs of Gynecological Cancer Survivors in Indonesia: A  
402 Qualitative Inquiry. *Semin Oncol Nurs*. 2021;000:151206.
- 403 8. Afiyanti Y, Gayatri D, Besral, dan Haryani. Unmet supportive care needs of Indonesian  
404 gynecological cancer survivors. *Enferm Clin*. 2019;29(Insc 2018):869–73.
- 405 9. Afiyanti Y, Setyowati, Milanti A, Young A. ‘Finally, I get to a climax’: the experiences of  
406 sexual relationships after a psychosexual intervention for Indonesian cervical cancer  
407 survivors and the husbands. *J Psychosoc Oncol*. 2020;0(0):1–17.
- 408 10. Malini H, Efendi F, Kadar KS, Lenggogeni DP, Sari YP. Health literacy and associated  
409 factors among patients with chronic diseases in Indonesia. *Journal of Public Health*  
410 (Germany). 2023;(0123456789).
- 411 11. Dewi, A., Supriyati, S., & Pangastuti HS. Literasi Kesehatan Pasien Kanker Tentang  
412 Traditional Complementary And Alternative Medicine ( TCAM ) logo. *Berita Kedokteran*  
413 *Masyarakat*. 2018;34(11):3–7.
- 414 12. Lokich E. Gynecologic Cancer Survivorship. *Obstet Gynecol Clin North Am*.  
415 2019;46(1):165–78.
- 416 13. Afiyanti Y, Milanti A, Putri RH. Supportive care needs in predicting the quality of life  
417 among gynecological cancer patients. *Canadian Oncology Nursing Journal*. 2018;28(1):1–  
418 26.

- 419 14. Putri RH, Afiyanti Y, Ungsianik T, Milanti A. Supportive care needs and quality of life of  
420 patients with gynecological cancer undergoing therapy. *Enferm Clin*. 2017;27(Suppl. Part  
421 I):222–6.
- 422 15. World Health Organization. WHO Releases First Guideline on Digital Health  
423 Interventions [Internet]. 2019 [cited 2023 Aug 24]. Available from:  
424 [https://www.who.int/news-room/detail/17-04-2019-who-releases-first-guideline-on-](https://www.who.int/news-room/detail/17-04-2019-who-releases-first-guideline-on-digital-health-interventions)  
425 [digital-health-interventions](https://www.who.int/news-room/detail/17-04-2019-who-releases-first-guideline-on-digital-health-interventions)
- 426 16. ElKefi S, Asan O. How technology impacts communication between cancer patients and  
427 their health care providers: A systematic literature review. *Int J Med Inform*.  
428 2021;149(December 2020):104430.
- 429 17. Escriva Bouley G, Leroy T, Bernetière C, Paquienseguy F, Desfriches-Doria O, Préau M.  
430 Digital health interventions to help living with cancer: A systematic review of  
431 participants' engagement and psychosocial effects. *Psychooncology*. 2018;27(12):2677–  
432 86.
- 433 18. Roberts AL, Fisher A, Smith L, Heinrich M, Potts HWW. Digital health behaviour change  
434 interventions targeting physical activity and diet in cancer survivors: a systematic review  
435 and meta-analysis. *Journal of Cancer Survivorship*. 2017;11(6):704–19.
- 436 19. Devine KA, Viola AS, Coups EJ, Wu YP. Digital Health Interventions for Adolescent and  
437 Young Adult Cancer Survivors. *JCO Clin Cancer Inform*. 2018;(2):1–15.
- 438 20. Jongerius C, Russo S, Mazzocco K, Pravettoni G. Research-Tested Mobile Apps for  
439 Breast Cancer Care: Systematic Review. *JMIR Mhealth Uhealth*. 2019;7(2):1–15.
- 440 21. Larson JL, Rosen AB, Wilson FA. The effect of telehealth interventions on quality of life  
441 of cancer patients: A systematic review and meta-analysis. *Telemedicine and e-Health*.  
442 2018;24(6):397–405.
- 443 22. Galica J, Giroux J, Francis JA, Maheu C. Coping with fear of cancer recurrence among  
444 ovarian cancer survivors living in small urban and rural settings: A qualitative descriptive  
445 study. *European Journal of Oncology Nursing*. 2020;44(November 2019):101705.
- 446 23. Beesley VL, Alemayehu C, Webb PM. A systematic literature review of trials of  
447 survivorship interventions for women with gynaecological cancer and their caregivers.  
448 *Eur J Cancer Care (Engl)*. 2019;28(3):701–10.
- 449 24. Schlumbrecht M, Sun C, Huang M, Milbourne A, Bodurka D. Gynecologic cancer  
450 survivor preferences for long-term surveillance. *BMC Cancer*. 2018;18(1):1–10.
- 451 25. O'Brien KK, Ibáñez-Carrasco F, Carusone SC, Bayoumi AM, Tang A, McDuff K, et al.  
452 Piloting an online telecoaching community-based exercise intervention with adults living  
453 with HIV: Protocol for a mixed-methods implementation science study. *BMJ Open*. 2023  
454 Mar 30;13(3).

- 455 26. Eldridge SM, Lancaster GA, Campbell MJ, Thabane L, Hopewell S, Coleman CL, et al.  
456 Defining feasibility and pilot studies in preparation for randomised controlled trials:  
457 Development of a conceptual framework. *PLoS One*. 2016;11(3):1–22.
- 458 27. Henneghan AM, Van Dyk KM, Ackerman RA, Paolillo EW, Moore RC. Assessing  
459 cancer-related cognitive function in the context of everyday life using ecological mobile  
460 cognitive testing: A protocol for a prospective quantitative study. *Digit Health*. 2023;9:1–  
461 9.
- 462 28. Riba MB, Donovan KA, Andersen B, Braun Ii, Breitbart WS, Brewer BW, et al. Distress  
463 management, version 3.2019. *JNCCN Journal of the National Comprehensive Cancer  
464 Network*. 2019;17(10):1229–49.
- 465 29. Roth AJ, Kornblith AB, Batel-Copel L, Peabody E, Scher HI, Holland JC. Rapid  
466 screening for psychologic distress in men with prostate carcinoma: A pilot study. *Cancer*.  
467 1998;82(10):1904–8.
- 468 30. Sun H, Thapa S, Wang B, Fu X, Yu S. A Systematic Review and Meta-analysis of the  
469 Distress Thermometer for Screening Distress in Asian Patients with Cancer. *J Clin  
470 Psychol Med Settings*. 2021;28(2):212–20.
- 471 31. McElroy JA, Waindim F, Weston K, Wilson G. A systematic review of the translation and  
472 validation methods used for the national comprehensive cancer network distress  
473 thermometer in non-English speaking countries. *Psychooncology*. 2022 Aug  
474 1;31(8):1267–74.
- 475 32. Iskandarsyah A, de Klerk C, Suardi DR, Soemitro MP, Sadarjoen SS, Passchier J. The  
476 Distress Thermometer and its validity: a first psychometric study in Indonesian women  
477 with breast cancer. *PLoS One*. 2013 Jan;8(2):e56353.
- 478 33. Almohammadi A, Alqarni A, Alraddadi R, Alzahrani F. Assessment of Patients '   
479 Knowledge in Managing Side Effects of Chemotherapy : Case of King Abdul-Aziz  
480 University Hospital. 2020;334–8.
- 481 34. Bandura a. Self-efficacy: toward a unifying theory of behavioral change. *Psychol Rev*.  
482 1977 Mar;84(2):191–215.
- 483 35. Bandura A. *Self-Efficacy: The Exercise of Control*. New York: Henry Holt & Co; 1997.
- 484 36. Herts KL, Khaled MM, Stanton AL. Correlates of self-efficacy for disease management in  
485 adolescent/young adult cancer survivors: A systematic review. *Health Psychology*.  
486 2017;36(3):192–205.
- 487 37. White LL, Cohen MZ, Berger AM, Kupzyk KA, Bierman PJ. Self-efficacy for  
488 management of symptoms and symptom distress in adults with cancer: An integrative  
489 review. *Oncol Nurs Forum*. 2019;46(1):113–28.
- 490 38. Self-Efficacy for Managing Chronic Disease 6-item Scale. :1–2.

- 491 39. Melin J, Fors A, Jakobsson S, Krabbe D, Björkman I. Self-Efficacy to Manage Chronic  
492 Disease (SEMCD) scale: translation and evaluation of measurement properties for a  
493 swedish version. *Archives of Public Health*. 2023;81(1):1–12.
- 494 40. Marconcin P, Tomé G, Carnide F, Yázigi F, Campos P, Pais S, et al. Translation, cultural  
495 adaptation and validation of the self-efficacy to manage chronic disease 6-Item scale for  
496 European Portuguese. *Acta Reumatol Port*. 2021;46(1):15–22.
- 497 41. Freund T, Gensichen J, Goetz K, Szecsenyi J, Mahler C. Evaluating self-efficacy for  
498 managing chronic disease: Psychometric properties of the six-item Self-Efficacy Scale in  
499 Germany. *J Eval Clin Pract*. 2013;19(1):39–43.
- 500 42. Enjezab B, Rejaezadeh M, Bokaie M, Salimi H. The Effectiveness of Acceptance and  
501 Commitment Therapy (ACT) on Sexual Self-Efficacy and Sexual Quality of Life in  
502 Reproductive-Age Women: A Randomized Controlled Trial. *J Sex Marital Ther*.  
503 2021;47(8):764–72.
- 504 43. Maasoumi R, Lamyian M, Montazeri A, Azin SA, Aguilar-Vafaie ME, Hajizadeh E. The  
505 sexual quality of life-female (SQOL-F) questionnaire: Translation and psychometric  
506 properties of the Iranian version. *Reprod Health*. 2013;10(1):2–7.
- 507 44. Sim-Sim M, Aaberg V, Gómez-Cantarino S, Dias H, Caldeira E, Soto-Fernandez I, et al.  
508 Sexual Quality of Life-Female (SQoL-F): Cultural Adaptation and Validation of European  
509 Portuguese Version. *Healthcare (Switzerland)*. 2022;10(2).
- 510 45. Mehnert-Theuerkauf A, Hufeld JM, Esser P, Goerling U, Hermann M, Zimmermann T, et  
511 al. Prevalence of mental disorders, psychosocial distress, and perceived need for  
512 psychosocial support in cancer patients and their relatives stratified by biopsychosocial  
513 factors: rationale, study design, and methods of a prospective multi-center observation.  
514 *Front Psychol*. 2023;14(April).
- 515 46. Juliastuti D, Dean J, Afyanti Y, Fitzgerald L. Inter-related factors influencing sexual  
516 quality of life among women living with HIV in Banten Province, Indonesia: A mixed  
517 methods study. *Kesmas*. 2021 May 1;16(2):120–30.
- 518 47. BC Cancer Agency. Gynecological Cancer Survivorship Care Plan. Public Health Agency  
519 of Canada; 2012.

520  
521

522

523